


## PHARMACEUTICAL 2022



## Virpax Pharmaceuticals Inc. Rank 77 of 466





## PHARMACEUTICAL 2022





## Virpax Pharmaceuticals Inc. Rank 77 of 466

The relative strengths and weaknesses of Virpax Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Virpax Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 252%, being 174% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	39,572
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,088
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	93
Other Liabilities	0
Other Net Income	0
Other Revenues	62
Property and Equipment	0
Research and Development	4,839
Selling, General and Administrative Expense	7,186

Output Variable	Value in 1000 USD
Assets	39,572
Liabilities	2,088
Expenses	12,118
Revenues	62
Stockholders Equity	37,485
Net Income	-12,056
Comprehensive Net Income	-12,056
Economic Capital Ratio	252%

